{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:10:53Z","timestamp":1788945053452,"version":"build-2803163510"},"reference-count":159,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"DOI":"10.1080\/14728214.2026.2731005","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T16:50:56Z","timestamp":1788627056000},"page":"1-19","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Recent advances in hidradenitis suppurativa therapeutics: a focus on existing and future medical therapeutics"],"prefix":"10.1080","author":[{"given":"Camila R.","family":"Marquez","sequence":"first","affiliation":[{"name":"University of Washington School of Medicine","place":["Seattle, USA"]},{"name":"University of Illinois College of Medicine","place":["Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Joshi","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine","place":["Seattle, USA"]},{"name":"Creighton University School of Medicine","place":["Phoenix, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Gawey","sequence":"additional","affiliation":[{"name":"LSU Health Sciences Center","place":["New Orleans, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey N.","family":"Giuffre","sequence":"additional","affiliation":[{"name":"Washington State University","place":["Spokane, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Khem","sequence":"additional","affiliation":[{"name":"Washington State University","place":["Spokane, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[{"name":"University of Southern California","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/BJD.14038"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40257-025-00940-0"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/FMED.2021.676241"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.090"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2023.12.004"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.068"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000530758"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.08.064"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.5021\/AD.2021.33.6.515"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1708853"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae216"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40257-024-00911-X"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000526019"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1201\/b16633-12"},{"key":"e_1_3_4_17_1","unstructured":"HUMIRA\u00ae (adalimumab) for hidradenitis suppurativa (HS). [cited 2025 Aug 24]. Available from: https:\/\/www.humira.com\/hidradenitis-suppurativa"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1504370"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.040"},{"key":"e_1_3_4_20_1","unstructured":"FDA approves novartis cosentyx\u00ae as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade | novartis. [cited 2025 Aug 17]. Available from: https:\/\/www.novartis.com\/news\/media-releases\/fda-approves-novartis-cosentyx-first-new-biologic-treatment-option-hidradenitis-suppurativa-patients-nearly-decade"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/BJD\/LJAE098"},{"key":"e_1_3_4_22_1","unstructured":"HS dosing | COSENTYX\u00ae (secukinumab). [cited 2025 Aug 24]. Available from: https:\/\/www.cosentyx.com\/hidradenitis-suppurativa\/treatment-dosing"},{"key":"e_1_3_4_23_1","unstructured":"UCB receives U.S. FDA approval for BIMZELX[\u00ae] (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa | UCB. [cited 2025 Aug 18]. Available from: https:\/\/www.ucb.com\/newsroom\/press-releases\/article\/ucb-receives-us-fda-approval-for-bimzelxr-bimekizumab-bkzx-as-the-first-il-17a-and-il-17f-inhibitor-for-adults-with-moderate-to-severe-hidradenitis-suppurativa"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00101-6"},{"key":"e_1_3_4_25_1","unstructured":"BIMZELX[\u00ae]\u25bc(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa (HS) | UCB. [cited 2025 Aug 18]. Available from: https:\/\/www.ucb.com\/newsroom\/press-releases\/article\/bimzelxrvbimekizumab-two-year-data-at-ehsf-2025-demonstrate-sustained-disease-control-in-hidradenitis-suppurativa-hs"},{"key":"e_1_3_4_26_1","unstructured":"Taking BIMZELX\u00ae (bimekizumab-bkzx) for Hidradenitis Suppurativa. [cited 2025 Aug 24]. Available from: https:\/\/www.bimzelx.com\/hidradenitis-suppurativa\/dosing"},{"key":"e_1_3_4_27_1","unstructured":"Hidradenitis suppurativa market size to reach USD 4.6 billion by 2035 impelled by awareness expansion and better treatment access - BioSpace. [cited 2025 Aug 16]. Available from: https:\/\/www.biospace.com\/press-releases\/hidradenitis-suppurativa-market-size-to-reach-usd-4-6-billion-by-2035-impelled-by-awareness-expansion-and-better-treatment-access"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMADERMATOL.2021.1677"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000542389\/4400220\/000542389.PDF"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000536389"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/ACS.JMEDCHEM.9B01916"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177747"},{"key":"e_1_3_4_33_1","unstructured":"Study Details | study to assess efficacy Safety and tolerability of remibrutinib in Adult patients with Moderate to severe hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06840392?cond=NCT06840392&rank=1"},{"key":"e_1_3_4_34_1","unstructured":"epocrates Web. [cited 2025 Aug 16]. Available from: https:\/\/www.epocrates.com\/online\/article\/aad-2024-remibrutinib-well-tolerated-for-moderate-to-severe-hidradenitis"},{"key":"e_1_3_4_35_1","unstructured":"Study Details | a phase 3 study to assess efficacy Safety and tolerability of remibrutinib in Adult patients with Moderate to severe hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06799000?cond=NCT06799000&rank=1"},{"key":"e_1_3_4_36_1","unstructured":"A phase 3 study to assess efficacy Safety and tolerability of remibrutinib in Adult and adolescent patients with Moderate to severe hidradenitis suppurativa | novartis. [cited 2025 Oct 19]. Available from: https:\/\/www.novartis.com\/clinicaltrials\/study\/nct06840392"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00297-1"},{"key":"e_1_3_4_38_1","unstructured":"Study Details | studying complement inhibition in patients with Moderate to severe hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03001622"},{"key":"e_1_3_4_39_1","unstructured":"Study Details | efficacy and Safety study of IFX-1 in patients with Moderate to severe hidradenitis suppurativa (HS) | ClinicalTrials.Gov. [cited 2025 Jul 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03487276"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf398"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40265-021-01643-6"},{"key":"e_1_3_4_42_1","unstructured":"Study Details | evaluation of Safety and efficacy of Avacopan in subjects with Moderate to severe hidradenitis suppurativa (AURORA) | ClinicalTrials.Gov. [cited 2025 Jul 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03852472"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.07.121"},{"key":"e_1_3_4_44_1","unstructured":"ChemoCentryx announces positive topline results of phase II AURORA clinical trial of Avacopan in the treatment of hidradenitis suppurativa (HS) - BioSpace. [cited 2025 Aug 18]. Available from: https:\/\/www.biospace.com\/chemocentryx-announces-positive-topline-results-of-phase-ii-aurora-clinical-trial-of-avacopan-in-the-treatment-of-hidradenitis-suppurativa-hs"},{"key":"e_1_3_4_45_1","unstructured":"INF904. [cited 2025 Jul 5]. Available from: https:\/\/www.inflarx.de\/Home\/Research-Development\/INF904.html"},{"key":"e_1_3_4_46_1","unstructured":"Study Details | Evaluate Safety and Pharmacokinetics of INF904 in subjects with Moderate to severe chronic spontaneous urticaria or hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06555328"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40121-023-00759-4"},{"key":"e_1_3_4_48_1","unstructured":"Study Details | Safety and efficacy study of BDB-001 injection in patients with Moderate to severe hidradenitis suppurativa (HS) | ClinicalTrials.Gov. [cited 2025 Jul 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05103423?a=6"},{"key":"e_1_3_4_49_1","unstructured":"Study Details | efficacy and Safety study of BDB-001 injection in patients with Moderate to severe hidradenitis suppurativa (HS) | ClinicalTrials.Gov. [cited 2025 Jul 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05093855?a=5"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1831880"},{"key":"e_1_3_4_51_1","unstructured":"Study Details | a study to Evaluate RIST4721 in hidradenitis suppurativa (HS) | ClinicalTrials.Gov. [cited 2025 Jul 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05348681"},{"key":"e_1_3_4_52_1","unstructured":"Study Details | a study of LY3041658 in adults with hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04493502"},{"key":"e_1_3_4_53_1","unstructured":"Promising phase 2 data on septa-specific monoclonal antibody for Hidradenitis Suppurativa. [cited 2025 Aug 19]. Available from: https:\/\/www.hcplive.com\/view\/phase-2-data-septa-specific-monoclonal-antibody-hidradenitis-suppurativa"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.10.015"},{"key":"e_1_3_4_55_1","unstructured":"Study Details | a study of eltrekibart (LY3041658) in Adult Participants with Moderate to severe hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06046729"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/CPT.1053"},{"key":"e_1_3_4_57_1","unstructured":"FDA approves BRINSUPRITM (brensocatib) as the first and only treatment for non-Cystic Fibrosis Bronchiectasis a serious chronic Lung disease -. 2025 Aug 12 [cited 2025 Aug 19]. Available from: https:\/\/investor.insmed.com\/2025-08-12-FDA-Approves-BRINSUPRI-TM-brensocatib-as-the-First-and-Only-Treatment-for-Non-Cystic-Fibrosis-Bronchiectasis -a-Serious -Chronic-Lung-Disease"},{"key":"e_1_3_4_58_1","unstructured":"Study Details | a study of the efficacy and Safety of brensocatib in adults with Moderate to severe hidradenitis suppurativa (HS) | ClinicalTrials.Gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06685835"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/LUPUS-2018-000261"},{"key":"e_1_3_4_60_1","unstructured":"Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus. [cited 2025 Aug 19]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2021\/saphnelo-approved-in-the-us-for-sle.html#"},{"key":"e_1_3_4_61_1","unstructured":"Study Details | Anifrolumab for hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06374212"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/IMR.12621"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2018.01682"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2024.100263"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40259-023-00587-5"},{"key":"e_1_3_4_66_1","unstructured":"Study Details | Anakinra as a treatment for hydradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 26]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT01516749"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMADERMATOL.2015.3903"},{"key":"e_1_3_4_68_1","unstructured":"Study Details | MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB | ClinicalTrials.Gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02643654?cond=Hidradenitis%20Suppurativa&intr=MABp1&rank=1"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.10.024"},{"key":"e_1_3_4_70_1","unstructured":"Study Details | a study to Evaluate the efficacy Safety and tolerability of Bermekimab in patients with hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04019041"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/BJD\/LJAE318"},{"key":"e_1_3_4_72_1","unstructured":"Study Details | a study of Bermekimab for the treatment of Participants with Moderate to severe hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04988308"},{"key":"e_1_3_4_73_1","unstructured":"Lutikizumab showed positive results in a phase 2 trial of adults with Moderate to severe hidradenitis Suppurativa as Program advances to phase 3. 2024 Jan 8 [cited 2025 Jul 26]. Available from: https:\/\/news.abbvie.com\/2024-01-08-Lutikizumab-Showed-Positive-Results-in-a-Phase-2-Trial-of-Adults-with-Moderate-to-Severe-Hidradenitis-Suppurativa-as-Program-Advances-to-Phase-3"},{"key":"e_1_3_4_74_1","unstructured":"Study Details | a study to assess disease activity and Safety of Lutikizumab in Adult and adolescent Participants with Moderate to severe hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06468228"},{"key":"e_1_3_4_75_1","unstructured":"Study Details | assessment of the Safety tolerability and efficacy of MEDI8968 in subjects with Moderate to severe hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Aug 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01838499?cond=NCT01838499&term=Hidradenitis%20Suppurativa&rank=1"},{"key":"e_1_3_4_76_1","unstructured":"Study Details | a study to Evaluate the efficacy and Safety of AVTX-009 in patients with Moderate to severe hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06603077"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/S13555-024-01207-Y"},{"key":"e_1_3_4_78_1","unstructured":"Study Details | a proof of concept study to Evaluate the Effectiveness of Ustekinumab in hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01704534"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14338"},{"key":"e_1_3_4_80_1","unstructured":"Study Details | NCT05322473 | evaluation of Sonelokimab for the treatment of patients with active Moderate to severe hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Aug 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05322473"},{"key":"e_1_3_4_81_1","unstructured":"MoonLake immunotherapeutics achieves landmark milestone with positive phase 2 results for Nanobody\u00ae sonelokimab in hidradenitis suppurativa | MoonLake immunotherapeutics. [cited 2025 Aug 18]. Available from: https:\/\/ir.moonlaketx.com\/news-releases\/news-release-details\/moonlake-immunotherapeutics-achieves-landmark-milestone-positive"},{"key":"e_1_3_4_82_1","unstructured":"MoonLake immunotherapeutics reports on week 16 results of the VELA phase 3\u00a0hidradenitis suppurativa program with the Nanobody\u00ae sonelokimab | MoonLake immunotherapeutics. [cited 2025 Oct 19]. Available from: https:\/\/ir.moonlaketx.com\/news-releases\/news-release-details\/moonlake-immunotherapeutics-reports-week-16-results-vela-phase-3"},{"key":"e_1_3_4_83_1","unstructured":"Study Details | a study to Evaluate the efficacy and Safety of subcutaneous Sonelokimab compared with placebo in Adult Participants with Moderate to severe hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06411899"},{"key":"e_1_3_4_84_1","unstructured":"Study Details | study to Evaluate the efficacy and Safety of subcutaneous Sonelokimab compared with placebo in Adult Participants with Moderate to severe hidradenitis suppurativa | ClinicalTrials.Gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06411379"},{"key":"e_1_3_4_85_1","unstructured":"Study Details | an open-label single-arm study to Evaluate Pharmacokinetics and Safety of subcutaneous Sonelokimab in adolescents with Moderate to severe hidradenitis suppurativa (VELA-TEEN). ClinicalTrials.gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06768671"},{"key":"e_1_3_4_86_1","unstructured":"Study Details | Efficacy Safety and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients | ClinicalTrials.gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02421172"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/EXD.14619"},{"key":"e_1_3_4_88_1","unstructured":"National Library of Medicine. Hidradenitis Suppurativa Phase 2b Study of Izokibep. [cited 2025 Jul 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05355805"},{"key":"e_1_3_4_89_1","unstructured":"Study Details | Hidradenitis Suppurativa Study of Izokibep | ClinicalTrials.gov. [cited 2025 Jul 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05905783"},{"key":"e_1_3_4_90_1","unstructured":"Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep | Affibody Medical AB. [cited 2025 Sep 1]. Available from: https:\/\/www.affibody.se\/press\/positive-phase-3-results-in-hidradenitis-suppurativa-further-strengthen-competitive-profile-of-izokibep\/"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1624463"},{"key":"e_1_3_4_92_1","unstructured":"Study Details | NCT06993610 | Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense | ClinicalTrials.gov. [cited 2026 May 24]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06993610?cond=tibulizumab&viewType=Card&rank=2"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S418748"},{"key":"e_1_3_4_94_1","unstructured":"Study Details | Guselkumab for Hidradenitis Suppurativa a Mode of Action Study. ClinicalTrials.gov. [cited 2025 Jul 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04061395"},{"key":"e_1_3_4_95_1","unstructured":"Study Details | A Study to Evaluate the Efficacy Safety and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) | ClinicalTrials.gov. [cited 2025 Jul 28]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03628924"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/S13555-023-00913-3"},{"key":"e_1_3_4_97_1","unstructured":"Study Details | A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | ClinicalTrials.gov. [cited 2025 Aug 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03926169"},{"key":"e_1_3_4_98_1","unstructured":"Study Details | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa | ClinicalTrials.gov. [cited 2025 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04856930?cond=NCT04856930&rank=1"},{"key":"e_1_3_4_99_1","unstructured":"AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa | AnaptysBio Inc. [cited 2025 Jul 19]. Available from: https:\/\/ir.anaptysbio.com\/news-releases\/news-release-details\/anaptysbio-reports-harp-phase-2-top-line-data-imsidolimab"},{"key":"e_1_3_4_100_1","unstructured":"Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) | AnaptysBio Inc. [cited 2025 Sep 1]. Available from: https:\/\/ir.anaptysbio.com\/news-releases\/news-release-details\/anaptys-announces-positive-top-line-phase-3-clinical-trial"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40265-022-01801-4"},{"key":"e_1_3_4_102_1","unstructured":"Study Details | A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa | ClinicalTrials.gov. [cited 2025 Aug 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04762277?cond=NCT04762277&rank=1"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1093\/BJD\/LJAE144"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.337"},{"key":"e_1_3_4_105_1","unstructured":"Study Details | Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa | ClinicalTrials.gov. [cited 2025 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05819398?cond=Spesolimab&term=hidradenitis%20suppurativa&aggFilters=phase:3&rank=1"},{"key":"e_1_3_4_106_1","unstructured":"Study Details | A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab | ClinicalTrials.gov. [cited 2025 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06241573?cond=Spesolimab&term=hidradenitis%20suppurativa&aggFilters=phase:3&rank=2"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1021\/ACS.JMEDCHEM.4C01305\/SUPPL_FILE\/JM4C01305_SI_001.PDF"},{"key":"e_1_3_4_108_1","unstructured":"Study Details | A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | ClinicalTrials.gov. [cited 2025 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06028230?cond=NCT06028230&rank=1"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2024.10.452"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1248\/BPB.B21-00609"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/ART.41953\/ABSTRACT"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDOA2300155"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/BJD.20969"},{"key":"e_1_3_4_114_1","unstructured":"Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa | Incyte. [cited 2025 Sep 1]. Available from: https:\/\/investor.incyte.com\/news-releases\/news-release-details\/incyte-announces-52-week-results-phase-2-study-evaluating"},{"key":"e_1_3_4_115_1","unstructured":"Study Details | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (STOP-HS1). ClinicalTrials.gov. [cited 2025 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05620823?cond=INCB054707&term=Hidradenitis%20Suppurativa&aggFilters=phase:3&rank=1"},{"key":"e_1_3_4_116_1","unstructured":"Study Details | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (STOP-HS2). ClinicalTrials.gov. [cited 2025 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05620836?cond=INCB054707&term=Hidradenitis%20Suppurativa&aggFilters=phase:3&rank=2"},{"key":"e_1_3_4_117_1","unstructured":"Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa | Incyte. [cited 2025 Aug 16]. Available from: https:\/\/investor.incyte.com\/news-releases\/news-release-details\/incyte-announces-positive-topline-results-two-phase-3-clinical"},{"key":"e_1_3_4_118_1","unstructured":"Study Details | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | ClinicalTrials.gov. [cited 2025 Aug 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06855498?cond=NCT06855498%20&rank=1"},{"key":"e_1_3_4_119_1","unstructured":"Study Details | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | ClinicalTrials.gov. [cited 2025 Aug 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06212999?cond=NCT06212999%20&rank=1"},{"key":"e_1_3_4_120_1","unstructured":"Drugs@FDA: FDA-Approved Drugs. [cited 2025 Jul 4]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=211675"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.12.046"},{"key":"e_1_3_4_122_1","unstructured":"Study Details | NCT05889182 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy | ClinicalTrials.gov. [cited 2025 Aug 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05889182"},{"key":"e_1_3_4_123_1","unstructured":"FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older | FDA. [cited 2025 Aug 24]. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older"},{"key":"e_1_3_4_124_1","unstructured":"Study Details | Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment | ClinicalTrials.gov. [cited 2025 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04414514?cond=NCT04414514&rank=1"},{"key":"e_1_3_4_125_1","unstructured":"Study Details | Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa | ClinicalTrials.gov. [cited 2025 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05635838?cond=NCT05635838&rank=1"},{"key":"e_1_3_4_126_1","unstructured":"Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura\u00ae) in Patients with Mild-to-Moderate Hidradenitis Suppurativa | Incyte. [cited 2025 Jul 26]. Available from: https:\/\/investor.incyte.com\/news-releases\/news-release-details\/incyte-announces-new-data-phase-2-study-evaluating-ruxolitinib"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.10.149"},{"key":"e_1_3_4_128_1","unstructured":"Study Details | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1). ClinicalTrials.gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06959225?cond=ruxolitinib&term=hidradenitis%20suppurativa&aggFilters=phase:3%202&rank=3"},{"key":"e_1_3_4_129_1","unstructured":"Study Details | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2). ClinicalTrials.gov. [cited 2025 Jul 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06958211?cond=ruxolitinib&term=hidradenitis%20suppurativa&aggFilters=phase:3%202&rank=4"},{"key":"e_1_3_4_130_1","unstructured":"Study Details | Tofacitinib for Immune Skin Conditions in Down Syndrome | ClinicalTrials.gov. [cited 2025 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04246372?cond=NCT04246372&rank=1"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.7554\/ELIFE.99323"},{"key":"e_1_3_4_132_1","unstructured":"Bristol Myers Squibb - U.S. Food and Drug Administration Approves SotyktuTM (deucravacitinib) Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis. [cited 2025 Jul 21]. Available from: https:\/\/news.bms.com\/news\/details\/2022\/U.S.-Food-and-Drug-Administration-Approves-Sotyktu-deucravacitinib-Oral-Treatment-for-Adults-with-Moderate-to-Severe-Plaque-Psoriasis\/default.aspx"},{"key":"e_1_3_4_133_1","unstructured":"Study Details | Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS). ClinicalTrials.gov. [cited 2025 Jul 21]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05997277?cond=NCT05997277.&rank=1"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1038\/SJ.CR.7290257"},{"key":"e_1_3_4_135_1","unstructured":"Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa - BioSpace. [cited 2025 Jul 5]. Available from: https:\/\/www.biospace.com\/aclaris-therapeutics-announces-preliminary-topline-data-from-12-week-phase-2a-study-of-oral-zunsemetinib-ati-450-for-moderate-to-severe-hidradenitis-suppurativa"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1007\/S13555-024-01308-8"},{"key":"e_1_3_4_137_1","unstructured":"Study Details | Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | ClinicalTrials.gov. [cited 2025 Jul 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06118099?cond=NCT06118099&rank=1"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2018.01048"},{"key":"e_1_3_4_139_1","unstructured":"FDA APPROVES OTEZLA\u00ae (APREMILAST) FOR THE TREATMENT OF ADULT PATIENTS WITH PLAQUE PSORIASIS REGARDLESS OF SEVERITY LEVEL| Amgen. [cited 2025 Aug 24]. Available from: https:\/\/www.amgen.com\/newsroom\/press-releases\/2021\/12\/fda-approves-otezla-apremilast-for-the-treatment-of-adult-patients-with-plaque-psoriasis-regardless-of-severity-level"},{"key":"e_1_3_4_140_1","unstructured":"Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective Open-Label Phase 2 Study - PubMed. [cited 2025 Jul 21]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30811140\/"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.076"},{"key":"e_1_3_4_142_1","unstructured":"Study Details | Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa | ClinicalTrials.gov. [cited 2025 Jul 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05040698?cond=NCT05040698&rank=1"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22052719"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40262-017-0627-0"},{"key":"e_1_3_4_145_1","unstructured":"Infliximab - StatPearls - NCBI Bookshelf. [cited 2025 Aug 24]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500021\/"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.06.050"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/mjd.2003.554"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.1111\/J.1600-0625.2009.00967.X"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100483"},{"key":"e_1_3_4_150_1","unstructured":"Study Details | A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa | ClinicalTrials.gov. [cited 2025 Jul 21]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05849922?cond=SAR442970&rank=2"},{"key":"e_1_3_4_151_1","unstructured":"Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed. [cited 2025 Aug 24]. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2025\/2025-04-24-05-30-00-3067075"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.065"},{"key":"e_1_3_4_153_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09808-7"},{"key":"e_1_3_4_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2025.05.007"},{"key":"e_1_3_4_155_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14609"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01601-0"},{"key":"e_1_3_4_157_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf188"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2215181"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2446432"},{"key":"e_1_3_4_160_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.2373"},{"key":"e_1_3_4_161_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18135"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2026.2731005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14728214.2026.2731005","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2026.2731005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:04:40Z","timestamp":1788944680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2026.2731005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":159,"alternative-id":["10.1080\/14728214.2026.2731005"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2026.2731005","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}